Entrada Therapeutics, Inc. (NASDAQ:TRDA)
| Market Cap | 276.01M+36.2% |
| Revenue (ttm) | 4.69M-94.1% |
| Net Income | -165.78M-126.0% |
| EPS | -3.97-122.6% |
| Shares Out | 38.82M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 381,775 |
| Open | 7.55 |
| Previous Close | 7.52 |
| Day's Range | 7.01 - 7.55 |
| 52-Week Range | 5.02 - 16.45 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 14.00(+96.91%) |
| Earnings Date | Nov 5, 2026 |
About TRDA
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TRDA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TRDA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TRDA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TRDA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TRDA Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Personnel related (including stock-based compensation) | $11.79M | 30.63% |
| ENTR-601-44 | $7.21M | 18.73% |
| Facility related and other | $5.50M | 14.29% |
| DMD franchise-wide | $3.49M | 9.05% |
| ENTR-601-45 | $3.03M | 7.87% |
| Interest and other income | $2.23M | 5.80% |
| ENTR-601-50 | $1.73M | 4.49% |
| ENTR-601-51 | $1.26M | 3.27% |
| Collaboration revenue | $898.00K | 2.33% |
| Ocular programs | $649.00K | 1.69% |
| Other preclinical and discovery | $406.00K | 1.05% |
| Collaboration services | $301.00K | 0.78% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New TRDA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TRDA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TRDA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $6.48M |
| IWMiShares Russell 2000 ETF | $5.42M |
| IWNiShares Russell 2000 Value ETF | $1.93M |
| VXFVanguard Extended Market ETF | $1.92M |
| IBBiShares Biotechnology ETF | $1.45M |
| VTWOVanguard Russell 2000 ETF | $1.13M |
Estimated from each fund’s disclosed top holdings × AUM
TRDA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TRDA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score